| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114 [Y. B., H. D. S., R. K. J.]; Debiopharm S.A., 1003 Lausanne, Switzerland [G. G-E.]; and The Norwegian University of Science and Technology, 7034 Trondheim, Norway [C. B.]
Elevated tumor interstitial fluid pressure (IFP) is partly responsible for the poor penetration and distribution of therapeutic agents in solid tumors. The etiology of tumor interstitial hypertension is poorly understood. We have postulated that the solid stress generated by tumor cells growing in a confined space compresses blood vessels and increases tumor microvascular pressure and IFP. To test the hypothesis that neoplastic cell loss would decompress blood vessels and lower IFP, we induced apoptosis in tumors with paclitaxel and docetaxel. Taxanes inhibited the growth of the murine mammary carcinoma (MCa-IV) and of the human soft tissue sarcoma (HSTS-26T). Taxanes induced apoptosis and reduced the density of intact neoplastic cells in both MCa-IV and HSTS-26T. To determine whether neoplastic cell loss decompressed blood vessels, we measured the diameter of tumor vessels in HSTS-26T tumors implanted in transparent dorsal skin fold chambers. At 48 and 96 h after paclitaxel, the diameter of tumor vessels was significantly increased. The increase in vascular diameters was associated with reductions in microvascular pressure and IFP. The changes in neoplastic cell density and IFP were also correlated. In the human glioblastoma U87, which is resistant to paclitaxel, the IFP and cellular density were not modified by paclitaxel treatment. Collectively, these results support the hypothesis that solid stress generated by neoplastic cell proliferation increases vascular resistance and IFP. The increase in vessel diameter induced by paclitaxel and docetaxel suggests that taxanes could improve tumor response by increasing the vascular surface area for delivery of therapeutic agents.
This article has been cited by other articles:
|
|
 |
|
  C. R. Schnell, F. Stauffer, P. R. Allegrini, T. O'Reilly, P. M.J. McSheehy, C. Dartois, M. Stumm, R. Cozens, A. Littlewood-Evans, C. Garcia-Echeverria, et al. Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging Cancer Res., August 15, 2008; 68(16): 6598 - 6607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nagano, J. Y. Perentes, R. K. Jain, and Y. Boucher Cancer Cell Death Enhances the Penetration and Efficacy of Oncolytic Herpes Simplex Virus in Tumors Cancer Res., May 15, 2008; 68(10): 3795 - 3802. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Gonzalez-Angulo and G. N. Hortobagyi Optimal Schedule of Paclitaxel: Weekly Is Better J. Clin. Oncol., April 1, 2008; 26(10): 1585 - 1587. [Full Text] [PDF]
|
|
|
|
|
|
K. Pachmann, O. Camara, A. Kavallaris, S. Krauspe, N. Malarski, M. Gajda, T. Kroll, C. Jorke, U. Hammer, A. Altendorf-Hofmann, et al. Monitoring the Response of Circulating Epithelial Tumor Cells to Adjuvant Chemotherapy in Breast Cancer Allows Detection of Patients at Risk of Early Relapse J. Clin. Oncol., March 10, 2008; 26(8): 1208 - 1215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhang, L. Xiang, R. Hassan, and I. Pastan Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors PNAS, October 23, 2007; 104(43): 17099 - 17104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Tredan, C. M. Galmarini, K. Patel, and I. F. Tannock Drug Resistance and the Solid Tumor Microenvironment J Natl Cancer Inst, October 3, 2007; 99(19): 1441 - 1454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O Camara, M Rengsberger, A Egbe, A Koch, M Gajda, U Hammer, C Jorke, C Rabenstein, M Untch, and K Pachmann The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer Ann. Onc., September 1, 2007; 18(9): 1484 - 1492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Lu, M. G. Wientjes, Z. Lu, and J. L.-S. Au Tumor Priming Enhances Delivery and Efficacy of Nanomedicines J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 80 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. V. Kozin, F. Winkler, I. Garkavtsev, D. J. Hicklin, R. K. Jain, and Y. Boucher Human Tumor Xenografts Recurring after Radiotherapy Are More Sensitive to Anti-Vascular Endothelial Growth Factor Receptor-2 Treatment than Treatment-Naive Tumors Cancer Res., June 1, 2007; 67(11): 5076 - 5082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Wiedenmann, D. Valdecanas, N. Hunter, S. Hyde, T. A. Buchholz, L. Milas, and K. A. Mason 130-nm Albumin-Bound Paclitaxel Enhances Tumor Radiocurability and Therapeutic Gain Clin. Cancer Res., March 15, 2007; 13(6): 1868 - 1874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Generali, A. Berruti, M. P. Brizzi, L. Campo, S. Bonardi, S. Wigfield, A. Bersiga, G. Allevi, M. Milani, S. Aguggini, et al. Hypoxia-Inducible Factor-1{alpha} Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer Clin. Cancer Res., August 1, 2006; 12(15): 4562 - 4568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang, L. Xiang, R. Hassan, C. H. Paik, J. A. Carrasquillo, B.-s. Jang, N. Le, M. Ho, and I. Pastan Synergistic Antitumor Activity of Taxol and Immunotoxin SS1P in Tumor-Bearing Mice Clin. Cancer Res., August 1, 2006; 12(15): 4695 - 4701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Cairns, I. Papandreou, and N. Denko Overcoming Physiologic Barriers to Cancer Treatment by Molecularly Targeting the Tumor Microenvironment Mol. Cancer Res., February 1, 2006; 4(2): 61 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ferretti, P. R. Allegrini, T. O'Reilly, C. Schnell, M. Stumm, M. Wartmann, J. Wood, and P. M.J. McSheehy Patupilone Induced Vascular Disruption in Orthotopic Rodent Tumor Models Detected by Magnetic Resonance Imaging and Interstitial Fluid Pressure Clin. Cancer Res., November 1, 2005; 11(21): 7773 - 7784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Green, A. U. Buzdar, T. Smith, N. K. Ibrahim, V. Valero, M. F. Rosales, M. Cristofanilli, D. J. Booser, L. Pusztai, E. Rivera, et al. Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks J. Clin. Oncol., September 1, 2005; 23(25): 5983 - 5992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Flessner, J. Choi, K. Credit, R. Deverkadra, and K. Henderson Resistance of Tumor Interstitial Pressure to the Penetration of Intraperitoneally Delivered Antibodies into Metastatic Ovarian Tumors Clin. Cancer Res., April 15, 2005; 11(8): 3117 - 3125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Taghian, R. Abi-Raad, S. I. Assaad, A. Casty, M. Ancukiewicz, E. Yeh, P. Molokhia, K. Attia, T. Sullivan, I. Kuter, et al. Paclitaxel Decreases the Interstitial Fluid Pressure and Improves Oxygenation in Breast Cancers in Patients Treated With Neoadjuvant Chemotherapy: Clinical Implications J. Clin. Oncol., March 20, 2005; 23(9): 1951 - 1961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Criscuoli, M. Nguyen, and B. P. Eliceiri Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability Blood, February 15, 2005; 105(4): 1508 - 1514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.C. Jayson, G.J.M. Parker, S. Mullamitha, J.W. Valle, M. Saunders, L. Broughton, J. Lawrance, B. Carrington, C. Roberts, B. Issa, et al. Blockade of Platelet-Derived Growth Factor Receptor-Beta by CDP860, a Humanized, PEGylated di-Fab', Leads to Fluid Accumulation and Is Associated With Increased Tumor Vascularized Volume J. Clin. Oncol., February 10, 2005; 23(5): 973 - 981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-P. Gerber and N. Ferrara Pharmacology and Pharmacodynamics of Bevacizumab as Monotherapy or in Combination with Cytotoxic Therapy in Preclinical Studies Cancer Res., February 1, 2005; 65(3): 671 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Jain Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy Science, January 7, 2005; 307(5706): 58 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Eikenes, O. S. Bruland, C. Brekken, and C. d. L. Davies Collagenase Increases the Transcapillary Pressure Gradient and Improves the Uptake and Distribution of Monoclonal Antibodies in Human Osteosarcoma Xenografts Cancer Res., July 15, 2004; 64(14): 4768 - 4773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sonveaux, C. Dessy, P. Martinive, X. Havaux, B. F. Jordan, B. Gallez, V. Gregoire, J.-L. Balligand, and O. Feron Endothelin-1 Is a Critical Mediator of Myogenic Tone in Tumor Arterioles: Implications for Cancer Treatment Cancer Res., May 1, 2004; 64(9): 3209 - 3214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. van Hensbergen, H. J. Broxterman, S. Rana, P. J. van Diest, M. C. A. Duyndam, K. Hoekman, H. M. Pinedo, and E. Boven Reduced Growth, Increased Vascular Area, and Reduced Response to Cisplatin in CD13-Overexpressing Human Ovarian Cancer Xenografts Clin. Cancer Res., February 1, 2004; 10(3): 1180 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. F. Hwang, K. Yokoi, C. D. Bucana, R. Tsan, J. J. Killion, D. B. Evans, and I. J. Fidler Inhibition of Platelet-Derived Growth Factor Receptor Phosphorylation by STI571 (Gleevec) Reduces Growth and Metastasis of Human Pancreatic Carcinoma in an Orthotopic Nude Mouse Model Clin. Cancer Res., December 15, 2003; 9(17): 6534 - 6544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Znati, M. Rosenstein, T. D. McKee, E. Brown, D. Turner, W. D. Bloomer, S. Watkins, R. K. Jain, and Y. Boucher Irradiation Reduces Interstitial Fluid Transport and Increases the Collagen Content in Tumors Clin. Cancer Res., November 15, 2003; 9(15): 5508 - 5513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Galbraith, R. J. Maxwell, M. A. Lodge, G. M. Tozer, J. Wilson, N. J. Taylor, J. J. Stirling, L. Sena, A. R. Padhani, and G. J.S. Rustin Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance Imaging J. Clin. Oncol., August 1, 2003; 21(15): 2831 - 2842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Delille, P. J. Slanetz, E. D. Yeh, E. F. Halpern, D. B. Kopans, and L. Garrido Invasive Ductal Breast Carcinoma Response to Neoadjuvant Chemotherapy: Noninvasive Monitoring with Functional MR Imaging— Pilot Study Radiology, July 1, 2003; 228(1): 63 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Pietras, K. Rubin, T. Sjoblom, E. Buchdunger, M. Sjoquist, C.-H. Heldin, and A. Ostman Inhibition of PDGF Receptor Signaling in Tumor Stroma Enhances Antitumor Effect of Chemotherapy Cancer Res., October 1, 2002; 62(19): 5476 - 5484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Herbst, N. A. Mullani, D. W. Davis, K. R. Hess, D. J. McConkey, C. Charnsangavej, M. S. O'Reilly, H.-W. Kim, C. Baker, J. Roach, et al. Development of Biologic Markers of Response and Assessment of Antiangiogenic Activity in a Clinical Trial of Human Recombinant Endostatin J. Clin. Oncol., September 15, 2002; 20(18): 3804 - 3814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. Scappaticci Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies J. Clin. Oncol., September 15, 2002; 20(18): 3906 - 3927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ramanujan, A. Pluen, T. D. McKee, E. B. Brown, Y. Boucher, and R. K. Jain Diffusion and Convection in Collagen Gels: Implications for Transport in the Tumor Interstitium Biophys. J., September 1, 2002; 83(3): 1650 - 1660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Milosevic, A. Fyles, D. Hedley, M. Pintilie, W. Levin, L. Manchul, and R. Hill Interstitial Fluid Pressure Predicts Survival in Patients with Cervix Cancer Independent of Clinical Prognostic Factors and Tumor Oxygen Measurements Cancer Res., September 1, 2001; 61(17): 6400 - 6405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Holden, Y. Lan, A. M. Pardo, J. S. Wesolowski, and S. D. Gillies Augmentation of Antitumor Activity of an Antibody-Interleukin 2 Immunocytokine with Chemotherapeutic Agents Clin. Cancer Res., September 1, 2001; 7(9): 2862 - 2869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Jang, M. G. Wientjes, and J. L.-S. Au Enhancement of Paclitaxel Delivery to Solid Tumors by Apoptosis-Inducing Pretreatment: Effect of Treatment Schedule J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 1035 - 1042. [Abstract] [Full Text]
|
|
|
|
|
|
K. D. Miller, C. J. Sweeney, and G. W. Sledge Jr Redefining the Target: Chemotherapeutics as Antiangiogenics J. Clin. Oncol., February 15, 2001; 19(4): 1195 - 1206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. F. Symmans, M. D. Volm, R. L. Shapiro, A. B. Perkins, A. Y. Kim, S. Demaria, H. T. Yee, H. McMullen, R. Oratz, P. Klein, et al. Paclitaxel-induced Apoptosis and Mitotic Arrest Assessed by Serial Fine-Needle Aspiration: Implications for Early Prediction of Breast Cancer Response to Neoadjuvant Treatment Clin. Cancer Res., December 1, 2000; 6(12): 4610 - 4617. [Abstract] [Full Text]
|
|
|
|
|
|
C.-G. Lee, M. Heijn, E. di Tomaso, G. Griffon-Etienne, M. Ancukiewicz, C. Koike, K. R. Park, N. Ferrara, R. K. Jain, H. D. Suit, et al. Anti-Vascular Endothelial Growth Factor Treatment Augments Tumor Radiation Response under Normoxic or Hypoxic Conditions Cancer Res., October 1, 2000; 60(19): 5565 - 5570. [Abstract] [Full Text]
|
|
|
|
|
|
M. I. Koukourakis, G. Kyrias, S. Kakolyris, C. Kouroussis, C. Frangiadaki, A. Giatromanolaki, G. Retalis, and V. Georgoulias Subcutaneous Administration of Amifostine During Fractionated Radiotherapy: A Randomized Phase II Study J. Clin. Oncol., June 11, 2000; 18(11): 2226 - 2233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. McDonald, L. Munn, and R. K. Jain Vasculogenic Mimicry: How Convincing, How Novel, and How Significant? Am. J. Pathol., February 1, 2000; 156(2): 383 - 388. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
